Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Simulations Plus, Inc. has received a consensus rating of "Hold" from ten ratings firms, with one sell, five hold, and four buy recommendations.
• The average 12-month price target for Simulations Plus shares is $24.40, while TD Cowen initiated coverage with a $16.00 target.
• Simulations Plus reported earnings of $0.45 EPS for the last quarter, beating estimates, but revenue was below expectations at $20.36 million.

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) has been assigned a consensus rating of "Hold" from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $24.40.

A number of analysts have recently commented on SLP shares. TD Cowen initiated coverage on shares of Simulations Plus in a research report on Tuesday, September 30th. They issued a "hold" rating and a $16.00 price objective on the stock. Cowen initiated coverage on shares of Simulations Plus in a research note on Tuesday, September 30th. They issued a "hold" rating on the stock. JMP Securities reissued a "market perform" rating on shares of Simulations Plus in a research report on Wednesday, June 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Simulations Plus in a report on Wednesday. Finally, BTIG Research dropped their target price on Simulations Plus from $41.00 to $25.00 and set a "buy" rating on the stock in a report on Monday, July 7th.

Simulations Plus Price Performance

SLP stock opened at $16.47 on Thursday. The stock has a market capitalization of $331.49 million, a P/E ratio of -5.23 and a beta of 0.99. Simulations Plus has a fifty-two week low of $12.39 and a fifty-two week high of $37.67. The business has a 50-day moving average of $14.52 and a 200-day moving average of $21.24.

Simulations Plus (NASDAQ:SLP - Get Free Report) last announced its earnings results on Monday, July 14th. The technology company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.26 by $0.19. Simulations Plus had a positive return on equity of 11.62% and a negative net margin of 78.63%.The business had revenue of $20.36 million for the quarter, compared to analyst estimates of $22.83 million. During the same quarter last year, the firm earned $0.27 EPS. Simulations Plus's revenue for the quarter was up 9.8% compared to the same quarter last year. Equities analysts expect that Simulations Plus will post 1.09 EPS for the current year.

Hedge Funds Weigh In On Simulations Plus

Several hedge funds and other institutional investors have recently made changes to their positions in SLP. Rice Hall James & Associates LLC lifted its stake in Simulations Plus by 15.9% in the first quarter. Rice Hall James & Associates LLC now owns 106,082 shares of the technology company's stock valued at $2,601,000 after acquiring an additional 14,582 shares during the last quarter. GAMMA Investing LLC lifted its stake in Simulations Plus by 20,727.1% in the 1st quarter. GAMMA Investing LLC now owns 17,703 shares of the technology company's stock valued at $434,000 after purchasing an additional 17,618 shares during the last quarter. North Star Investment Management Corp. bought a new position in Simulations Plus during the first quarter worth about $1,300,000. Wellington Management Group LLP acquired a new position in Simulations Plus during the first quarter worth approximately $2,458,000. Finally, Fiera Capital Corp acquired a new position in Simulations Plus during the first quarter worth approximately $576,000. 78.08% of the stock is owned by institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.